1. Home
  2. Stock quotes
  3. IDEXX Laboratories
  4. Financial Ratios
IDEXX Laboratories logo
IDEXX Laboratories IDXX
$ 688.18 0.86%

Quarterly report 2025-Q3
added 11-03-2025

report update icon

IDEXX Laboratories Financial Ratios 2011-2025 | IDXX

Annual Financial Ratios IDEXX Laboratories

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

 42.4 56.1 63.0 60.9 76.3 57.1 47.8 62.2 48.7 33.8 43.6 32.2 29.7 29.7

P/S

 9.7 13.0 12.7 14.1 16.4 10.2 8.2 8.3 6.1 4.1 5.3 4.4 4.1 3.9

EPS

 10.8 10.2 8.1 8.7 6.8 5.0 4.3 3 2.5 2.1 1.8 1.8 3.2 2.9

EV (Enterprise Value)

 39.1 B 48.8 B 44.8 B 47 B 45.7 B 26 B 19.5 B 18 B 12.3 B 7.93 B 8.87 B 6.48 B 5.53 B 5.12 B

EBITDA per Share

 15.3 14.6 12.1 12.2 9.26 7.44 6.61 5.65 4.77 4.07 3.19 3.02 2.86 2.5

EV/EBITDA

 45.3 52.3 39.5 32.9 35.2 27.7 20.0 26.6 18.4 16.1 16.3

PEG

 2.64 3.18 3.72 2.93 4.26 3.94 1.07 2.9 2.52 2.41 15.39 3.6 2.17 1.82

P/B

 23.6 32.0 70.3 65.7 70.2 137.4 -1953.9 -304.2 -99.9 -77.3 67.4 11.7 8.3 8.9

P/CF

 40.5 52.3 78.8 60.0 68.5 80.4 65.1 55.2 40.1 48.7 45.3 36.1 32.3 28.8

ROE %

 55.65 56.92 111.56 107.95 91.94 240.53 -4083.52 -488.73 -205.19 -228.68 154.70 36.24 28.02 29.98

ROA %

 26.96 25.92 24.72 30.56 25.35 23.34 24.52 15.36 14.51 13.02 13.14 15.26 16.15 15.69

ROCE %

 50.70 47.53 59.48 55.69 40.57 49.93 64.07 58.27 58.75 49.84 46.20 35.47 37.66 39.77

Current Ratio

 1.9 1.8 1.3 1.4 1.4 0.9 0.8 1.0 0.9 1.0 0.9 1.4 1.4 1.2

DSO

 43.6 42.8 41.7 39.7 40.5 46.6 45.0 50.1 47.7 45.6 44.5 41.9 39.0 42.3

DIO

 91.6 92.8 85.3 65.9 65.1 68.4 65.1 68.8 72.1 96.9 87.4 78.4 86.6 84.9

DPO

 27.0 21.1 16.6 15.1 18.9 25.3 26.1 28.0 27.4 27.0 24.4 17.6 21.7 23.3

Operating Cycle

 135.2 135.6 127.0 105.6 105.6 115.0 110.1 118.9 119.8 142.5 131.9 120.3 125.6 127.2

Cash Conversion Cycle

 108.2 114.5 110.4 90.5 86.7 89.7 83.9 90.8 92.4 115.4 107.5 102.7 103.9 103.9

All numbers in USD currency

Quarterly Financial Ratios IDEXX Laboratories

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

 3.43 3.66 2.98 - 2.83 2.46 2.84 - 2.55 2.7 2.58 - 2.17 1.57 2.3 - 2.06 2.37 2.39 - 1.71 1.75 1.31 1.05 1.26 1.46 1.19 0.99 1.07 1.25 1.02 0.44 0.81 0.97 0.78 0.59 0.63 0.75 0.51 0.49 0.48 0.61 0.49 0.27 0.52 0.56 0.45 0.83 0.87 1.01 0.82 0.79 0.78 0.93 0.74 0.68 0.68 0.85 0.64

EBITDA per Share

 - - 4.31 - - - 3.96 - - - 3.72 - 3.94 2.13 3.26 - 3.56 3.04 3.19 - 2.85 2.82 1.96 1.35 2.38 2.4 1.79 1.34 2.07 2.15 1.53 1.12 1.85 1.86 1.28 - 1.63 1.59 1.03 - 1.34 1.3 0.94 0.73 1.16 1.09 1.62 - 2.03 1.98 1.37 - 1.85 1.84 1.32 - 1.61 1.65 1.13

ROE %

 68.89 65.69 58.40 42.27 58.63 60.60 68.23 62.31 100.32 121.97 130.35 97.21 120.40 105.59 103.79 79.32 102.45 102.39 98.87 64.39 115.38 153.57 200.84 241.01 -710.21 -1751.78 -2965.16 -3963.32 -3133.81 -2283.88 -1299.09 -486.35 -463.97 -385.76 -290.02 -204.93 -209.31 -209.78 -215.41 -228.32 -153.52 -56.58 59.76 154.79 141.05 105.50 67.23 36.24 34.71 32.63 30.27 28.02 28.25 28.65 29.60 29.98 7.14 9.02 6.79

ROA %

 31.44 30.28 27.40 19.93 26.80 26.73 28.59 22.31 29.16 29.14 28.81 21.82 29.16 22.17 30.57 24.52 30.89 29.92 28.01 17.74 22.68 22.24 22.61 23.34 23.97 24.10 24.31 24.52 21.19 19.24 17.15 15.36 16.55 16.12 15.53 14.51 14.09 13.40 12.87 13.02 11.89 12.66 12.93 13.14 14.78 14.73 14.98 15.26 15.67 15.85 16.11 16.15 15.91 15.76 15.84 15.69 3.74 4.72 3.55

ROCE %

 62.54 58.90 52.67 36.93 49.94 49.97 53.40 44.00 60.89 64.76 89.04 71.38 84.28 80.30 55.84 42.13 52.18 49.32 45.89 29.77 40.22 42.81 46.36 49.95 54.55 57.23 61.37 64.09 62.85 61.71 60.02 58.29 58.55 59.22 59.40 58.77 55.53 52.32 49.12 48.52 43.88 45.06 45.55 46.21 48.18 44.07 39.77 35.47 36.41 36.73 37.13 37.66 37.87 38.29 39.42 39.77 9.45 12.00 9.01

Current Ratio

 1.9 1.8 1.8 1.9 1.9 1.9 1.9 1.8 1.7 1.6 1.4 1.3 1.2 - 1.3 1.4 1.5 1.4 1.4 1.4 1.4 1.4 1.4 1.1 1.1 1.1 1.1 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 1.1 1.1 1.1 1.1 1.7 1.7 1.7 1.7 2.4 2.4 2.4 2.4 2.1 2.1 2.1 2.1

DSO

 46.5 44.7 45.7 - 48.9 47.3 45.6 - 45.6 43.9 42.9 - 21.0 21.3 42.0 - 42.7 42.2 41.8 - 41.9 47.4 43.8 40.6 40.6 39.6 41.0 41.3 41.6 39.1 41.0 42.3 43.5 42.1 43.4 42.1 41.6 40.0 42.9 43.0 42.3 41.6 40.6 39.5 36.3 35.6 39.3 40.7 42.6 40.9 40.7 39.5 40.0 37.6 39.5 42.0 42.8 40.6 -

DIO

 84.8 86.8 94.6 - 92.5 91.5 94.8 - 98.0 96.7 96.9 - 48.3 39.7 77.1 - 67.6 63.2 64.7 - 64.0 74.2 69.2 - 68.3 67.9 68.7 - 65.9 63.7 65.7 - 68.8 69.3 72.2 - 71.5 70.0 83.3 - 94.6 95.4 95.4 - 86.0 85.3 84.8 - 79.8 78.6 84.5 - 88.8 85.2 84.5 - 85.4 84.4 -

DPO

 25.8 26.0 28.5 - 27.4 27.9 28.1 - 27.3 27.7 29.1 - 15.0 15.9 32.0 - 24.3 24.4 24.0 - 22.7 26.3 25.1 - 25.3 25.1 26.4 - 26.5 25.6 26.6 - 28.0 28.3 28.4 - 27.2 26.6 27.1 - 26.4 26.6 26.6 - 24.0 23.8 21.6 - 17.9 17.6 20.1 - 22.2 21.3 22.2 - 23.4 23.2 -

Operating Cycle

 131.3 131.5 140.4 - 141.4 138.8 140.4 - 143.5 140.6 139.8 - 69.4 61.0 119.1 - 110.3 105.5 106.6 - 105.9 121.6 113.0 40.6 109.0 107.5 109.8 41.3 107.6 102.8 106.7 42.3 112.3 111.4 115.5 42.1 113.2 110.0 126.2 43.0 136.9 137.0 136.1 39.5 122.2 120.9 124.1 40.7 122.5 119.5 125.2 39.5 128.8 122.8 124.1 42.0 128.2 125.0 -

Cash Conversion Cycle

 105.5 105.5 111.9 - 114.0 110.9 112.4 - 116.2 112.9 110.7 - 54.4 45.1 87.1 - 86.0 81.0 82.5 - 83.2 95.2 87.9 40.6 83.7 82.4 83.3 41.3 81.1 77.2 80.2 42.3 84.3 83.1 87.1 42.1 86.0 83.4 99.2 43.0 110.5 110.4 109.5 39.5 98.2 97.1 102.5 40.7 104.5 101.9 105.1 39.5 106.6 101.5 101.9 42.0 104.8 101.8 -

All numbers in USD currency

Multiples are an important financial analysis tool for the company IDEXX Laboratories, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Akumin Akumin
AKU
 		- -17.87 % $ 25.9 M canadaCanada
Centogene N.V. Centogene N.V.
CNTG
 		- -6.23 % $ 30.6 M germanyGermany
Brainsway Ltd. Brainsway Ltd.
BWAY
 		$ 19.29 -1.73 % $ 99.4 M israelIsrael
Chembio Diagnostics Chembio Diagnostics
CEMI
 		- 0.22 % $ 16.8 M usaUSA
Castle Biosciences Castle Biosciences
CSTL
 		$ 40.09 -0.27 % $ 1.11 B usaUSA
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
 		$ 21.26 -2.34 % $ 229 M chinaChina
Accelerate Diagnostics Accelerate Diagnostics
AXDX
 		- -61.36 % $ 2.46 M usaUSA
Biocept Biocept
BIOC
 		- -13.05 % $ 7.29 M usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
 		$ 10.04 -0.99 % $ 285 M israelIsrael
Enzo Biochem Enzo Biochem
ENZ
 		- -8.98 % $ 14.8 K usaUSA
BioNano Genomics BioNano Genomics
BNGO
 		$ 1.52 -0.65 % $ 1.93 M usaUSA
Danaher Corporation Danaher Corporation
DHR
 		$ 231.47 0.28 % $ 169 B usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
 		$ 101.54 -0.05 % $ 18.8 B usaUSA
DexCom DexCom
DXCM
 		$ 67.42 0.84 % $ 26 B usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
 		- - $ 562 M britainBritain
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
 		- -20.0 % $ 1.06 M usaUSA
Fulgent Genetics Fulgent Genetics
FLGT
 		$ 27.01 -0.55 % $ 817 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
 		- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
 		- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
 		- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
 		- 0.12 % $ 80.1 M chinaChina
DermTech DermTech
DMTK
 		- -11.32 % $ 2.94 M usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
 		- - $ 10.7 B usaUSA
CareDx, Inc CareDx, Inc
CDNA
 		$ 19.73 -1.45 % $ 1.06 B usaUSA
Celcuity Celcuity
CELC
 		$ 102.61 0.25 % $ 4.05 B usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
 		$ 3.42 3.64 % $ 109 K usaUSA
Co-Diagnostics Co-Diagnostics
CODX
 		$ 0.24 -1.79 % $ 7.04 M usaUSA
IQVIA Holdings IQVIA Holdings
IQV
 		$ 226.02 0.39 % $ 41 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
 		- -34.28 % $ 263 K israelIsrael
Guardant Health Guardant Health
GH
 		$ 102.38 -0.12 % $ 12.6 B usaUSA
NeoGenomics NeoGenomics
NEO
 		$ 12.3 -0.97 % $ 1.56 B usaUSA
Neogen Corporation Neogen Corporation
NEOG
 		$ 7.14 -0.14 % $ 1.55 B usaUSA
Aspira Women's Health Aspira Women's Health
AWH
 		- -6.19 % $ 10.5 M usaUSA
National Research Corporation National Research Corporation
NRC
 		$ 18.81 -1.05 % $ 462 M usaUSA
Heska Corporation Heska Corporation
HSKA
 		- - $ 1.31 B usaUSA
OPKO Health OPKO Health
OPK
 		$ 1.3 -0.76 % $ 902 M usaUSA
Organovo Holdings Organovo Holdings
ONVO
 		- -2.3 % $ 19.4 M usaUSA
OpGen OpGen
OPGN
 		- -16.95 % $ 1.54 M usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
 		$ 1.88 3.3 % $ 477 M usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
 		$ 1 417.16 0.18 % $ 30.1 B schweizSchweiz
Illumina Illumina
ILMN
 		$ 135.32 -0.64 % $ 21.5 B usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
 		$ 203.16 0.14 % $ 10.4 B usaUSA
ENDRA Life Sciences ENDRA Life Sciences
NDRA
 		$ 5.1 - $ 2.74 M usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
 		$ 26.98 0.37 % $ 20 B niderlandNiderland
Personalis Personalis
PSNL
 		$ 8.41 -0.12 % $ 498 M usaUSA
PerkinElmer PerkinElmer
PKI
 		- -0.91 % $ 14.7 B usaUSA
Quidel Corporation Quidel Corporation
QDEL
 		$ 28.91 1.12 % $ 1.22 B usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
 		$ 175.92 0.48 % $ 19.5 B usaUSA
Biodesix Biodesix
BDSX
 		$ 6.82 1.04 % $ 884 M usaUSA
Precipio Precipio
PRPO
 		$ 23.89 2.56 % $ 31 M usaUSA